3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
10
Gynecologic
2
Head & Neck
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Cisplatin
620
pembrolizumab
323
Radiotherapy
319
Cetuximab
275
Docetaxel
221
Radiotherapy, Intensity-Modulated
210
Carboplatin
197
Fluorouracil
196
Paclitaxel
159
Nivolumab
138
Gemcitabine
124
Magnetic Resonance Spectroscopy
94
Radiation
85
Drug Therapy
77
Capecitabine
76
toripalimab
75
Surgical Procedures, Operative
62
durvalumab
60
Biopsy
52
Cyclophosphamide
50
Chemoradiotherapy
47
camrelizumab
46
Specimen Handling
46
Erlotinib Hydrochloride
46
Radiosurgery
45
130-nm albumin-bound paclitaxel
44
Standard of Care
43
tislelizumab
42
Platinum
41
Bevacizumab
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Imlunestrant
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled